NATCO Pharma has addressed queries regarding recent news items, confirming its plans to launch Semaglutide in India in March 2026, following CDSCO approval on February 14, 2026. The company stated that its partnership with Eris Lifesciences Ltd for this product is routine business with no material financial impact. Furthermore, NATCO confirmed awareness of no undisclosed information that could explain unusual trading activity prior to this announcement. Trading Movement DisclosureWhen questioned about awareness of any unpublished price-sensitive information that could explain recent movements in the company’s trading, NATCO explicitly stated: “No”. Material Impact AssessmentRegarding the potential financial impact of the article being discussed, NATCO confirmed that, as of the date of this communication, there is no material financial impact stemming from the article on the company.

Source: Mint February 25, 2026 04:44 UTC